VolitionRx subsidiary CEO Dr. Butera to depart Jan 31, 2026; position eliminated

VOLITIONRX LTD

Volition Veterinary CEO Dr. Salvatore Thomas Butera given termination notice, effective Jan 31, 2026.
CEO position eliminated as part of ongoing cost-realignment efforts; duties redistributed.
Dr. Butera expected to stay as part-time consultant post-termination under agreed terms.
Departure not due to any disagreement with company on operations, policies, or practices.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.